Brainstorm Cell Therapeutics Inc (BCLI) Price

Brainstorm Cell Therapeutics, Inc. is a biotechnology company that develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. The company is headquartered in New York City, New York, and currently employs 27 full-time employees. It went public on May 28, 2003. The firm focuses on the development and commercialization of autologous cellular therapies for neurodegenerative conditions such as Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other related disorders. Its NurOwn cell therapy platform utilizes cell culture techniques to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative processes, promote neuronal survival, and improve neurological function. The company has completed a Phase III pivotal trial in ALS (NCT03280056), which evaluated the safety and efficacy of repeated administration of autologous MSC-NTF cells. Brainstorm Cell Therapeutics Ltd., a wholly owned subsidiary, holds exclusive rights to commercialize the NurOwn technology.